C WorldWide Group Holding A S Lowers Holdings in Accelerate Diagnostics Inc (AXDX)

C WorldWide Group Holding A S lessened its position in shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) by 15.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 155,367 shares of the medical research company’s stock after selling 28,943 shares during the period. C WorldWide Group Holding A S owned approximately 0.29% of Accelerate Diagnostics worth $3,566,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Chicago Capital LLC lifted its stake in shares of Accelerate Diagnostics by 86.5% during the second quarter. Chicago Capital LLC now owns 538,191 shares of the medical research company’s stock worth $12,002,000 after purchasing an additional 249,655 shares in the last quarter. Cornerstone Wealth Management LLC acquired a new position in shares of Accelerate Diagnostics during the second quarter worth about $210,000. CIBC Private Wealth Group LLC lifted its stake in shares of Accelerate Diagnostics by 33.8% during the second quarter. CIBC Private Wealth Group LLC now owns 60,550 shares of the medical research company’s stock worth $1,350,000 after purchasing an additional 15,305 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Accelerate Diagnostics by 4.2% during the second quarter. BlackRock Inc. now owns 1,750,891 shares of the medical research company’s stock worth $39,046,000 after purchasing an additional 70,447 shares in the last quarter. Finally, FMR LLC lifted its stake in shares of Accelerate Diagnostics by 97.8% during the second quarter. FMR LLC now owns 486,500 shares of the medical research company’s stock worth $10,849,000 after purchasing an additional 240,600 shares in the last quarter. 45.34% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:AXDX opened at $14.42 on Thursday. The company has a current ratio of 27.12, a quick ratio of 25.67 and a debt-to-equity ratio of 1.22. Accelerate Diagnostics Inc has a one year low of $13.25 and a one year high of $30.35.

Accelerate Diagnostics (NASDAQ:AXDX) last released its quarterly earnings results on Tuesday, November 6th. The medical research company reported ($0.41) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.41). Accelerate Diagnostics had a negative return on equity of 76.15% and a negative net margin of 1,365.75%. The business had revenue of $1.36 million for the quarter, compared to analysts’ expectations of $2.89 million. On average, equities research analysts predict that Accelerate Diagnostics Inc will post -1.66 earnings per share for the current year.

A number of brokerages have commented on AXDX. BidaskClub upgraded Accelerate Diagnostics from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 3rd. Zacks Investment Research cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Thursday, August 9th. JPMorgan Chase & Co. cut Accelerate Diagnostics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $25.00 to $16.00 in a research note on Wednesday. Finally, Piper Jaffray Companies restated a “buy” rating and set a $24.00 price objective on shares of Accelerate Diagnostics in a research note on Tuesday, August 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $21.67.

WARNING: This report was first reported by WKRB News and is owned by of WKRB News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.wkrb13.com/2018/11/08/c-worldwide-group-holding-a-s-lowers-holdings-in-accelerate-diagnostics-inc-axdx.html.

Accelerate Diagnostics Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Featured Article: How are Outstanding Shares Different from Authorized Shares?

Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics Inc (NASDAQ:AXDX).

Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply